Skinvisible, Inc. (OTCBB:SKVI) announced today that the South Korean patent office has granted a patent for Invisicare®, the company's polymer delivery system for topical dermatology products.
A total of twenty claims have been granted in the Korean patent which protects Invisicare in the areas of 'Topical Composition', 'Topical Composition Precursor', and 'Methods for Manufacturing and Using'. This is the fifth comprehensive international patent that Skinvisible has received for Invisicare® in addition to the four United States patents already granted. To date patents have been granted in India, Australia, China and Japan with a number of technology and product-specific patents pending globally.
"This latest patent strengthens the Company's growing proprietary position internationally, allowing us to present patent-protected opportunities to global pharmaceutical and consumer goods companies," said Mr. Terry Howlett, President and CEO of Skinvisible. "It also offers growing validation of the value of our technology as this patent, along with our other international patents, offers coverage of not only the composition, but also the manufacturing process and the dermatology indications our Invisicare technology is used for."
Invisicare is the core technology in Skinvisible's portfolio of products. Skinvisible licenses it products on an exclusive basis to companies seeking new products in the areas such as acne, dermatitis, actinic keratosis, anti-inflammatories, analgesics and antimicrobials. In addition, the company has developed a number of patent-protected and patent-pending cosmeceuticals such as moisturizers, sunscreens and sunless tanners. Invisicare adds unique benefits to these products including binding the product to the skin resisting wash-off and perspiration, controlling the release of the active; fast or slow and in some cases decreasing the use of actives and decreasing irritation. Along with patent protection, Skinvisible's products provide added benefits to topically formulated dermatology and consumer products that require rejuvenation, and add benefits to combat competition and generics.
AHN Biotechnologie GmbH – Premium private label manufacturing biotechnology